Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$331.8K+27.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kathy Lee-Sepsick
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 53
- Beta
- -2.07
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -18.76
Financials
Revenue
$331.8K+27.4%Net Income
$-4.47MEBITDA
$-4.20MFree Cash Flow
$-3.95MEPS (diluted)
$-1.33Shares Outstanding (diluted)
3.36M+640.1%Operating Expenses
$5.17MCash & Debt
$1.44MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.29M | $-18.63M | $-9.40 |
| 2024 | $1.63M | $-18.82M | $-16.80 |
| 2023 | $1.07M | $-14.25M | $-18.60 |
| 2022 | $1.21M | $-11.39M | $-19.40 |
| 2021 | $1.18M | $-7.54M | $-12.80 |
| 2020 | $1.04M | $-6.91M | $-11.80 |
| 2019 | $929.1K | $-11.27M | $-19.20 |
Valuation
FEMYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·27d ago·Negative
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated …
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…e able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and S…
View source ↗ - Newsbenzinga.com·47d ago·Negative
Femasys Secures FDA Pathway for Non-Surgical Contraceptive The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology.
View source ↗ - Newsglobenewswire.com·52d ago·Negative
… portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents -- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, a
View source ↗
Earnings
Tue, Nov 17(in 6 weeks)
Consensus estimate $-0.47 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.33 vs $-1.31miss
- Fri, May 8$0.10 vs $-1.33beat
- Thu, Mar 26$-1.25 vs $-1.67beat
- Tue, Nov 11$-2.00 vs $-2.30beat
- Fri, Aug 8$-3.20 vs $-3.27beat
- Thu, May 8$-4.60 vs $-3.40miss
Estimates and results for FEMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FEMY officers and directors.
- Bought
- $134k
- Sold
- —
5 trades
0 trades
- Mifek Jeffrey Geraldbought
- Sipos Jeremy Alexanderbought
- Canning John Charlesbought
- Elefant Dovbought
- Lee-sepsick Kathybought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FEMY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.